According to sources familiar with the decision, Ms. Devlin was hired Oct. 15 and will report to the FDA’s chief of staff.
Her hire comes roughly two months after Mylan finalized a $465 million settlement with federal government over accusations the drugmaker improperly classified EpiPens as a generic drug to overcharge Medicaid.
More articles on supply chain:
Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017
FDA announces steps, new guidance to nurture medical device innovations: 4 things to know
FDA issues warning letter to Magellan over violations related to blood-lead tests
Register to Attend Webinar
Presenters:
Mark Miller, Naviant|Jason Bui, UiPath|Jessica Wilborne, BlueCross BlueShield of North Carolina|Colleen Bubnack, UiPath
Next Up in Supply Chain
-
Phoenix-based Valleywise Health has become the first hospital in Arizona to implement the LifeBubble Umbilical Line Securement System for premature…
-
Vizient has unveiled three solutions designed to help health systems address performance gaps across the supply chain lifecycle. The tools…
-
Vizient has recognized suppliers for service, partnership and performance supporting its healthcare provider clients. Here are the suppliers recognized across…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.